A prospective study of the efficacy and safety of preoperative chemotherapy with gemcitabine+nab-paclitaxel therapy for resectable pancreatic body and tail cancer with splenic arteriovenous invasion by image.
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000040948
- Lead Sponsor
- Wakayama medical university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 49
Not provided
1. Cases with a history of severe drug hypersensitivity or drug allergy 2. Cases with a history of malignant tumor 3. Cases with active infection 4. Patients with peripheral sensory neuropathy (Grade 2 or higher) 5. Cases with a history of interstitial pneumonia or pulmonary fibrosis 6. Patients with uncontrolled ascites or pleural effusion 7. Cases with uncontrolled diabetes 8. Cases with Uncontrolled congestive heart failure, angina, hypertension, arrhythmia 9. Cases with history of neurologically or psychologically significant disease 10. Cases with diarrhea 11. Pregnant women, lactating women, and women who may be pregnant (will), or women and men who are not willing to contracept during the study period and for a certain period (180 days) after the last administration of study drug 12. Other cases that the doctor has determined to be unsuitable for participation in this clinical trial 13. Cases which conforms to Borderline Resectable/Unresectable of NCCN guidelines (Version 1.2020) by MDCT diagnosis. 14. Patients with active hepatitis B
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival after initiation of protocol treatment
- Secondary Outcome Measures
Name Time Method